BIOLASE Launches Soft-Tissue Diode Laser for Veterinary Applications

BIOLASE Launches Soft-Tissue Diode Laser for Veterinary Applications 
EPIC V-Series Boasts Numerous Special Features: Best Market Pricing;
Easy-Installation, Fully-Portable and Lightweight; Patented EZ
Tips(R) Technology for Dental and Surgical Procedures; Deep Tissue
Handpiece for Pain Therapy; Extended Battery Life; Wireless
Technology; Ergonomic Design and Intuitive Touch Screen; On-Line
IRVINE, CA -- (Marketwire) -- 02/26/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading dental laser manufacturer and distributor,
announced today that it launched the EPIC V-Series(TM) veterinary
soft-tissue diode laser, at the 85th Western Veterinary Conference
held this past February 18-20 in Las Vegas, Nevada. Over 6,500
veterinarians and 15,000 veterinary professionals attended the
The EPIC V-Series soft-tissue diode laser is based on the recently
released modular EPIC 10(TM) platform for medical and dental use. The
EPIC V-Series can be used for a wide range of veterinary
applications, including surgical, dental, and pain therapy
procedures. BIOLASE expects the EPIC V-Series will be available to
ship throughout North America and Europe, as well as several other
international markets, beginning early in the second quarter of 2013. 
The EPIC V-Series has a number of significant features including:
pricing that is over 30% less than the competition with comparable
technology; easy installation that can be performed by the office
staff in just a few minutes; fully-portable, cordless and wireless
with a battery that lasts an average work day for surgical and dental
procedures; a wireless foot pedal; the lightest unit in the Class 4,
10 watt category, which is ergonomically efficient when moving
between exam rooms or for use in a field environment; the only laser
on the market with our patented EZ Tips technology for dental and
surgical procedures; on-line training through webinars and podcasts;
the most aesthetically pleasing laser in veterinary medicine with
sleek black ergonomic design and intuitive touch screen; and platform
technology that was masterfully designed to allow BIOLASE to easily
transition into many different markets by simply adapting the
software and providing the appropriate delivery system. 
There are approxima
tely 70,000 veterinarians and nearly 34,000
veterinary clinics in North America. This market segment is expected
to increase 35 percent over the next 10 years. There are also more
than 100,000 veterinarians and 30,000 veterinary clinics in Europe.
Further, according to research from the Freedonia Group, a leading
international business research company, consumer spending on
domesticated animals in the U.S. alone is forecast to reach $44
billion in 2014.  
Federico Pignatelli, Chairman and Chief Executive Officer, commented,
"We are very pleased to introduce our EPIC soft-tissue diode laser
platform into the veterinary market, which is one of many exciting
opportunities available for our innovative patented laser
technologies. Families seek the very best care for their pets, and
the EPIC V-Series allows veterinarians to provide a significantly
improved and wider range of treatment solutions. During the recent
Western Veterinary Conference, we demonstrated the product and took
advance orders. We initially expect to address this fast-growing
market segment with our inside sales force and through an online
store, and ultimately expand it through a variety of strategic
distributor relationships. We are especially excited to apply our
technology and vast body of clinical experience in humans for the
treatment of gum disease, one of the most serious and common diseases
in cats, dogs and horses, and for chronic pain. We look forward to
joining other dental companies that have successfully entered and
grown their veterinary businesses, including Henry Schein, Inc.
(NASDAQ: HSIC), with Butler Schein Animal Health, and Patterson
Companies, Inc. (NASDAQ: PDCO), with Webster Veterinary Supply, now
called Patterson Veterinary." 
The EPIC V-Series features a 940nm wavelength with 10 watts of power
as well as an intuitive procedure-based graphical touchscreen. It
also uses BIOLASE's proprietary ComfortPulse(TM) control technology
that minimizes tissue damage and avoids pain-inducing heat buildup at
the surgical site. 
"The EPIC V-Series is more competitively priced than other
high-powered lasers in the veterinary market and features a
revolutionary and intuitive applications-based user interface. The
high-resolution touch screen is pre-programmed with several of the
most commonly performed veterinary soft tissue procedures, including
pain therapy, which is a highly popular treatment for pets. It is
also the only laser in the market with our patented EZ Tips
technology for dental and surgical procedures," Pignatelli concluded. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment; products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate approximately 290 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its imaging products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 22,000 lasers. Other products
under development address ophthalmology and other medical and
consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at, and
YouTube at  
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995
 Statements contained in this press release that refer to
BIOLASE's estimated or anticipated future results, expected outcomes
or approvals, or other non-historical facts are forward-looking
statements, as are any statements in this press release concerning
prospects related to BIOLASE's product introductions, strategic
initiatives, and anticipated financial performance. Forward-looking
statements can also be identified through the use of words such as
ticipates," "expects," "intends," "plans," "believes," "seeks,"
"estimates," "may," "will," and variations of these words or similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
perspective of existing trends and information and speak only as of
the date of this release. Actual results may differ materially from
BIOLASE's current expectations depending upon a number of factors
affecting BIOLASE's business. These factors include, among others,
adverse changes in general economic and market conditions,
competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of
new product offerings and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein. 
For further information, please contact: 
Lisa Wilson 
In-Site Communications, Inc. 
Press spacebar to pause and continue. Press esc to stop.